Ann Brady's most recent trade in Theravance Biopharma Inc was a trade of 8,369 Ordinary Shares done at an average price of $9.6 . Disclosure was reported to the exchange on Feb. 18, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | Ann B. Brady | PRESIDENT, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.61 per share. | 18 Feb 2022 | 8,369 | 110,319 (0%) | 0% | 9.6 | 80,426 | Ordinary Shares |
Theravance Biopharma Inc | Ann B. Brady | PRESIDENT, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 19 Nov 2021 | 3,169 | 118,688 (0%) | 0% | 8.4 | 26,493 | Ordinary Shares |
Theravance Biopharma Inc | Ann B. Brady | President, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.05 per share. | 20 Aug 2021 | 3,169 | 121,857 (0%) | 0% | 14.0 | 44,524 | Ordinary Shares |
Theravance Biopharma Inc | Ann B. Brady | President, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.80 per share. | 20 May 2021 | 3,169 | 125,026 (0%) | 0% | 17.8 | 56,408 | Ordinary Shares |
Theravance Biopharma Inc | Ann B. Brady | President, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.79 per share. | 20 Feb 2021 | 10,092 | 128,195 (0%) | 0% | 18.8 | 189,629 | Ordinary Shares |
Theravance Biopharma Inc | Ann B. Brady | President, TBIL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 40,000 | 138,287 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Ann Brady | President, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 20 Nov 2020 | 2,292 | 98,287 (0%) | 0% | 17.2 | 39,445 | Ordinary Shares |
Theravance Biopharma Inc | Ann Brady | President, TBIL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.22 per share. | 20 Aug 2020 | 2,292 | 100,579 (0%) | 0% | 18.2 | 41,760 | Ordinary Shares |